Somatostatin 5 receptor expression in prolactinomas: Is there a role for Pasireotide in the management of prolactinomas?

Pituitary · 2025 · PMC12583388 · PMID 41184667

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Although there was a trend towards higher D2 expression in patients showing the strongest lowering of PRL levels in vivo, the differences did not reach statistical significance (median D2R IRS 4.5, 3.5 and 8.0 for PRL suppression < 33%, > 33–67%, and > 67%, respectively).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.